Novartis Investigative Site

Alzira, Valencia 46600

0 studies enrolling now · 10 studies all time

What they study most

Cardiovascular Disease, Cushing's Disease, Cushings Disease, Heart Failure With Preserved Ejection Fraction, Hypertension, Primary Prevention of Atherosclerotic Cardiovascular Disease, Pulmonary Disease, Chronic Obstructive, Systolic Hypertension, Type 2 Diabetes Mellitus

Studies at this site

• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients — Completed
• Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease — Stopped early
• Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease — Completed
• An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension — Completed
• Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early
• 8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension — Completed